Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma

Rodriguez, Cesar; Lantz, Jeffrey W.; Akbar, Faisal; Lantz, Lyndsey; Dressler, Emily V.

doi:10.1016/j.clml.2019.09.362

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent observational, single-center study evaluated another modified version of RVd in TE NDMM, using fulldose lenalidomide and once-weekly bortezomib with the goal of minimizing PN risk. 62 Patients received induction or salvage therapy with lenalidomide 25 mg on days 1-21; bortezomib 1.3 mg/m 2 SC on days 1, 8, and 15; and dexamethasone 40 mg on days 1, 8, and 15 (28-day cycles). The overall response rate (ORR) was 87%, and 63% of patients achieved ≥VGPR.…”

Section: Rvd: Dose and Schedulementioning

confidence: 99%

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson,

Durie,

Rosiñol

et al. 2023

haematol

View full text Add to dashboard Cite

To improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet against both doublets and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of NDMM therapy, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.

show abstract

Section: Rvd: Dose and Schedulementioning

confidence: 99%